PAYER POLICY CHANGES

Q2040 Insurance Policy Changes

HCPCS Q2040 is officially defined as "Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion." HCPCS Q2040 is referenced in 2 tracked payer policy changes from Indiana Medicaid (IHCP) and Premera Blue Cross. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS Q2040 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Watch Q2040

Get one email when a payer policy names Q2040, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

See every payer rule for Q2040

Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for Q2040 in one place.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.